Navigation Links
CuraGen Sells Ownership of Belinostat to TopoTarget A/S
Date:4/22/2008

- CuraGen to receive approximately $45 million in cash, stock and future

milestone payments -

- Provides updated financial guidance for 2008 -

- Conference call to be hosted today at 9:00 a.m. EDT -

BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company, announced today that it has sold its ownership in belinostat, a Phase I/II histone deacetylase inhibitor, to TopoTarget A/S (Copenhagen Stock Exchange: TOPO) for approximately $39 million upfront in a combination of cash and stock. CuraGen will receive $26 million in cash and 5 million shares of TopoTarget common stock, currently valued at approximately $13 million, and $6 million in potential commercial milestone payments related to future net sales and sublicenses of belinostat. CuraGen will no longer have any funding requirements for belinostat as TopoTarget will immediately assume all financial and operational responsibility for the ongoing clinical development.

"CuraGen is working to create and unlock value within our portfolio while providing a strong and clear risk / reward profile for our investors. After a thorough review of our current strategic options, we feel the most effective use of our resources and best potential value creation opportunity for shareholders is based on CR011-vcMMAE, our un-partnered antibody-drug conjugate, currently in Phase II for the treatment of patients with metastatic melanoma and moving toward Phase II in metastatic breast cancer. We believe that today's deal represents a great opportunity for CuraGen, and its shareholders, by further strengthening our balance sheet by adding close to $45 million this year
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. CuraGen to Present at the BIO CEO & Investor Conference
9. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
10. Exelixis Sells 80% Stake in Artemis to Taconic
11. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014  United Therapeutics Corporation (NASDAQ: ... well as changes to Martine Rothblatt , Ph.D,s ... United Therapeutics announced the promotion of ... Officer and David Zaccardelli , Pharm.D. to Executive ... these promotions, Dr. Rothblatt,s title will change from Chairman ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... 2011 Reportlinker.com announces that a new market research ... The Future of In Vitro and In ... The term in-vitro/in-vivo diagnostics (IV2D) ... and pathology (imaging), as well as new software ...
... YORK, Jan. 25, 2011 Reportlinker.com announces ... available in its catalogue: ... Implications of Emerging Reimbursement, Technological and Market ... http://www.reportlinker.com/p0365288/Future-US-In-Vitro-Diagnostics-Market-Strategic-Implications-of-Emerging-Reimbursement-Technological-and-Market-Trends-through-2018.html How will ...
... 23, 2011 An interdisciplinary team from Columbia University ... together with researchers from the University,s departments of Physics ... single-molecule interactions on very short time scales using nanoscale ... 23 in Nature Nanotechnology , they show how, ...
Cached Biology Technology:Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 2Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 3Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2Columbia University researchers use nanoscale transistors to study single-molecule interactions 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... , Aug. 20, 2013  Today BluStor PMC, Inc. ... platform that protects the full stream of mobile ... vision for what,s possible using BluStor, the company ... at: http://www.blustor.com/whatspossible.php . (Logo:   ...
... fashion and look set to become big business in the baking ... by some chickens is prettier and some say tastier and cleaner-breaking ... from The University of Nottingham, we know what caused the eggs ... four-year research project just published in the journal, PLOS ONE ...
... of Iowa researchers have discovered what causes the lethal ... infection of heart valves that kills approximately 20,000 Americans ... culprits are superantigens -- toxins produced in large quantities ... disrupt the immune system, turning it from friend to ...
Cached Biology News:BluStor Introduces the World's First Platform to Protect the Full Stream of Mobile Security: Device, User, And Data 2Unscrambling the genetics of the chicken's 'blue' egg 2Bacterial toxins cause deadly heart disease 2